BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
May 31, 2010
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Microculture Kinetic diagnostic data

Data from a prospective, non-randomized, investigator-blinded study in 128 ovarian cancer patients showed that patients who received the best chemotherapy as predicted by DiaTech's MiCK assay had significantly improved OS (92% vs. 76%, p=0.01) and overall response rates (ORR; 82% vs. 54%, p=0.04)) vs. patients who received chemotherapy not recommended by the assay...

Read the full 241 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >